Q-omics provides the consensus-scored ZNF14 profile across patient tissues and cancer cell-line models. ZNF14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF14 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, ZNF14 RNA expression shows 21,735 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ZNF14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF14 survival associations across molecular data types. ZNF14 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF14 RNA expression–survival associations across cancer types. High ZNF14 expression shows favorable associations in KIRC, LUAD, HNSC, BRCA, UCS and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF14 RNA expression.
This table summarizes ZNF14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF14 shows lower tumor expression in THCA, KICH, LUAD and KIRP and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher ZNF14 RNA expression in normal versus tumor tissue (log2 FC = −1.005, t-test p < 0.001).
This table shows molecular features associated with ZNF14 in patient tissues and cancer cell lines. In patient samples, ZNF14 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
